TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9152568

Group type: EXPERIMENTAL
Intervention: 20-mg SR morphine sulfate capsule administered while fasting
Number of subjects: 24

Group type: COMPARATOR
Intervention: 20-mg SR morphine sulfate capsule administered after a high-fat meal
Number of subjects: 24
Study: 7525038

Group type: EXPERIMENTAL
Intervention: Pamidronate 60 mg every 4 weeks
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Pamidronate 60 mg every 2 weeks
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Pamidronate 90 mg every 4 weeks
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Pamidronate 30 mg every 2 weeks
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Narcotic scores
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Urinary calcium/creatinine and hydroxyproline/creatinine ratios
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Bone alkaline phosphatase concentrations
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Radiographic changes
Number of subjects: 61
Study: 3496872

Group type: EXPERIMENTAL
Intervention: Lid hygiene only
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Oral erythromycin (25 mg/kg twice daily for 14 days)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Topical chloramphenicol
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Severe conjunctivitis treatment
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Dacryocystitis
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Nonchlamydial conjunctivitis
Number of subjects: 128
Study: 29945711

Group type: EXPERIMENTAL
Intervention: Progesterone 200 mg vaginally daily from 22+0 to 24+0 weeks until 34+0 weeks' gestation
Number of subjects: 1197

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1197
Study: 28347354

Group type: EXPERIMENTAL
Intervention: Qualitative interviews with patients
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Qualitative interviews with clinician recruiters
Number of subjects: 19
Study: 26441180

Group type: EXPERIMENTAL
Intervention: Laparoscopic rectal resection (n=238)
Number of subjects: 475

Group type: COMPARATOR
Intervention: Open laparotomy and rectal resection (n=237)
Number of subjects: 475
Study: 22697581

Group type: EXPERIMENTAL
Intervention: Submerged healing (AuS)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Non-submerged healing (AuNS)
Number of subjects: 52
Study: 20951235

Group type: EXPERIMENTAL
Intervention: Exposure-based therapy for PTSD delivered via telehealth technology
Number of subjects: 0

Group type: COMPARATOR
Intervention: Exposure-based therapy for PTSD delivered in-person
Number of subjects: 0
Study: 18468736

Group type: EXPERIMENTAL
Intervention: Green tea extract (GTE) 400mg, three times daily for 12 weeks
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo (cellulose)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Green tea extract (GTE)
Number of subjects: 78
Study: 17178264

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 441

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 441

Group type: COMPARATOR
Intervention: Gln27 (Control)
Number of subjects: 441

Group type: COMPARATOR
Intervention: Glu27 (Control)
Number of subjects: 441
Study: 12812863

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral stress management training
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 48
Study: 10897742

Group type: EXPERIMENTAL
Intervention: Behavioural and relational techniques (sophrology, maintenance of the help relation, visualization-relaxation)
Number of subjects: 0
Study: 8866928

Group type: EXPERIMENTAL
Intervention: Nebulized morphine (50 mg in 4 ml saline)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral morphine (10 mg solution)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous morphine (5 mg)
Number of subjects: 0
Study: 1704212

Group type: EXPERIMENTAL
Intervention: Laser treatment
Number of subjects: 554

Group type: EXPERIMENTAL
Intervention: Loculated fluid pattern recognition
Number of subjects: 554
Study: 6403140

Group type: EXPERIMENTAL
Intervention: Glucose polymer supplementation (Caloreen) at 6 g/kg body weight daily
Number of subjects: 14

Group type: COMPARATOR
Intervention: Normal feeding
Number of subjects: 14
Study: 29466076

Group type: EXPERIMENTAL
Intervention: Therapeutic taping
Number of subjects: 43

Group type: COMPARATOR
Intervention: No taping (control)
Number of subjects: 43
Study: 29506460

Group type: EXPERIMENTAL
Intervention: PCT group (spot serum procalcitonin guided protocol)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional group (antibiotics stopped according to physicians' discretion)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: PCT group
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional group
Number of subjects: 50
Study: 27423790

Group type: EXPERIMENTAL
Intervention: Structured Problem Analysis of Raising Kids
Number of subjects: 4438

Group type: COMPARATOR
Intervention: Usual care (without structured interview)
Number of subjects: 4438
Study: 25074713

Group type: EXPERIMENTAL
Intervention: Dermal scarification (1 ml normal saline injection)
Number of subjects: 291

Group type: COMPARATOR
Intervention: Diclofenac sodium (75 mg intramuscular injection)
Number of subjects: 291
Study: 23130505

Group type: EXPERIMENTAL
Intervention: Walnut diet (1.5 oz/day of walnuts, 6 times/week)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Fish diet (8 oz/week of salmon)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control diet (no nuts or fish)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Walnut diet
Number of subjects: 25
Study: 20148782

Group type: EXPERIMENTAL
Intervention: Enhanced web-based intervention condition
Number of subjects: 2523

Group type: COMPARATOR
Intervention: Basic information-only control condition
Number of subjects: 2523
Study: 18981503

Group type: EXPERIMENTAL
Intervention: rDEN4Delta30-200,201 vaccine (10^5 PFU)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 15645213

Group type: EXPERIMENTAL
Intervention: Quadruple semitendinosus tendon (ST) autografts
Number of subjects: 41

Group type: COMPARATOR
Intervention: Patellar tendon (PT) autografts
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 41
Study: 12030916

Group type: EXPERIMENTAL
Intervention: Ghrelin (1.0 microg/kg i.v. at 0 min)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: GHRH (1.0 microm/kg i.v. at 0 min)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Somatostatin (SS, 2.0 microg/kg/h from -30 to +90 min)
Number of subjects: 7
Study: 9825368

Group type: EXPERIMENTAL
Intervention: Propafenone (600 mg single oral dose)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Propafenone
Number of subjects: 240
Study: 7644369

Group type: EXPERIMENTAL
Intervention: Air-bubble method
Number of subjects: 0

Group type: COMPARATOR
Intervention: Z-track method
Number of subjects: 0
Study: 2664816

Group type: EXPERIMENTAL
Intervention: Amoxycillin/clavulanic acid (1 g amoxycillin/200 mg clavulanic acid, 3 to 4 intravenous doses per day for mean 7.7 days, followed by 500 mg amoxycillin/125 mg clavulanic acid, 4 to 6 tablets per day for mean 11.2 days)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Standard regimen (3 to 4 g amoxycillin or ampicillin, 160 mg gentamicin, and 1.5 g metronidazole, parenteral therapy for mean 7.7 days, followed by 2 to 3 g amoxycillin or ampicillin and 1 to 1.5 g metronidazole daily for mean 11.1 days)
Number of subjects: 152
Study: 1145988

Group type: EXPERIMENTAL
Intervention: NISR 440 Polycarbonate Membrane
Number of subjects: 6

Group type: COMPARATOR
Intervention: Cuprophan
Number of subjects: 6
Study: 31385202

Group type: EXPERIMENTAL
Intervention: Choline plus magnesium (1000 mg choline bitartrate and 500 mg magnesium oxide)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Magnesium (500 mg magnesium oxide)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Choline (1000 mg choline bitartrate)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study: 29904752

Group type: EXPERIMENTAL
Intervention: HEMA-free 1-step self-etch adhesive (1SEa G-Bond)
Number of subjects: 52

Group type: COMPARATOR
Intervention: 3-step etch-and-rinse adhesive (3E&Ra Optibond FL)
Number of subjects: 52
Study: 27217412

Group type: EXPERIMENTAL
Intervention: High baPWV (highest quartile)
Number of subjects: 3310

Group type: EXPERIMENTAL
Intervention: Inadequate hypertension control
Number of subjects: 3310

Group type: EXPERIMENTAL
Intervention: High baPWV (highest quartile) and inadequate hypertension control
Number of subjects: 3310

Group type: EXPERIMENTAL
Intervention: High baPWV (highest quartile) with adequate hypertension control
Number of subjects: 3310

Group type: COMPARATOR
Intervention: Adequate hypertension control
Number of subjects: 3310
Study: 25578330

Group type: EXPERIMENTAL
Intervention: Standard care with glycopyrronium containing regimen
Number of subjects: 6000

Group type: COMPARATOR
Intervention: Standard care without glycopyrronium
Number of subjects: 6000
Study: 23473348

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 50 mg/d
Number of subjects: 874

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 874
Study: 20040338

Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg single oral dose
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 28
Study: 17976224

Group type: EXPERIMENTAL
Intervention: Inhaled iloprost (25 microg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intravenous nitroglycerine
Number of subjects: 20
Study: 16620263

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (202.65 kPa for 90 min, 5 days a week for 4 weeks)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (no hyperbaric therapy)
Number of subjects: 38
Study: 12568840

Group type: EXPERIMENTAL
Intervention: Oral 17beta‐E(2) administration from cycle day 20 until the next cycle day 2.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no E(2) administration).
Number of subjects: 60
Study: 11689712

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH) certoparin, self-administered for 3 months
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study: 9130335

Group type: EXPERIMENTAL
Intervention: Ethanol (0.9 g/kg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 7881142

Group type: EXPERIMENTAL
Intervention: Drain placed through the epigastric trocar site (Group 1)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No drain placed (Group 2)
Number of subjects: 100
Study: 3147477

Group type: EXPERIMENTAL
Intervention: 20 mg zolpidem (ZOL)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 50 mg chlorpromazine (CPZ)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Combination of ZOL + CPZ
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 6
Study: 1771605

Group type: EXPERIMENTAL
Intervention: Terbutaline (1 mg) via metered dose inhaler
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Terbutaline (2 mg total: 1 mg from each inhaler) via both inhalers
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Terbutaline (1 mg) via dry powder inhaler
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Terbutaline via dry powder inhaler
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Terbutaline via metered dose inhaler
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Terbutaline via both inhalers
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Terbutaline (1 mg) via both inhalers
Number of subjects: 20
Study: 1261205

Group type: EXPERIMENTAL
Intervention: Effervescent tablets
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Proprietary effervescent health salt
Number of subjects: 0
Study: 30541689

Group type: EXPERIMENTAL
Intervention: eHealth intervention for self-management of risk factors for cardiovascular disease and cognitive decline
Number of subjects: 343
Study: 28931167

Group type: EXPERIMENTAL
Intervention: Combined intervention
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: Social environmental intervention
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: Physical environmental intervention
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: All interventions
Number of subjects: 412
Study: 26512848

Group type: EXPERIMENTAL
Intervention: One muscle surgery
Number of subjects: 31

Group type: COMPARATOR
Intervention: Unilateral recess‐resect procedure
Number of subjects: 31
Study: 23885993

Group type: EXPERIMENTAL
Intervention: High-lignan FLX (0.41 g lignans)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Regular FLX (0.15 g lignans)
Number of subjects: 37
Study: 21157106

Group type: EXPERIMENTAL
Intervention: rosuvastatin 20mg
Number of subjects: 128

Group type: COMPARATOR
Intervention: atorvastatin 40mg
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 128
Study: 19118120

Group type: EXPERIMENTAL
Intervention: Combination therapy with losartan and lisinopril
Number of subjects: 1850

Group type: COMPARATOR
Intervention: Losartan alone
Number of subjects: 1850
Study: 17158129

Group type: EXPERIMENTAL
Intervention: Sevoflurane 0.8%
Number of subjects: 32

Group type: COMPARATOR
Intervention: Entonox (nitrous oxide 50%: oxygen 50%)
Number of subjects: 32
Study: 15166558

Group type: EXPERIMENTAL
Intervention: Auricular acupuncture (press needles at relaxation, tranquilizer point, and master cerebral point)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Sham acupuncture (press needles at shoulder, wrist, and extraneous auricular point)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Auricular acupuncture
Number of subjects: 66

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 66
Study: 11450179

Group type: EXPERIMENTAL
Intervention: Bupropion, sertraline, and venlafaxine as adjuncts to mood stabilizers
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids
Number of subjects: 500
Study: 9728431

Group type: EXPERIMENTAL
Intervention: PTFE grafts
Number of subjects: 131

Group type: COMPARATOR
Intervention: DHV grafts
Number of subjects: 131
Study: 7995315

Group type: EXPERIMENTAL
Intervention: Written information about the indications and limitations of benzodiazepines
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Both written and oral information
Number of subjects: 128

Group type: COMPARATOR
Intervention: No information (control group)
Number of subjects: 128
Study: 3056821

Group type: EXPERIMENTAL
Intervention: Sclerotherapy
Number of subjects: 140

Group type: COMPARATOR
Intervention: Conservative treatment (Control)
Number of subjects: 140
Study: 30325753

Group type: EXPERIMENTAL
Intervention: Adjuvant cisplatin-based chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antigen-specific immunotherapy (cancer vaccination)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibition (ICI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neoadjuvant administration of ICI
Number of subjects: 0
Study: 28450350

Group type: EXPERIMENTAL
Intervention: Rosuvastatin (20 mg/day) for 12 months
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: On-statin cholesterol efflux capacity
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Baseline HDL particle number
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Baseline cholesterol efflux capacity
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Baseline HDL cholesterol
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Baseline apolipoprotein A-I
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: HDL particle number (on-statin)
Number of subjects: 314
Study: 26111942

Group type: EXPERIMENTAL
Intervention: Physical Activity (PA)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Mindfulness Meditation (MM)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Heart Rate Variability Biofeedback (HRV-BF)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 76
Study: 23815547

Group type: EXPERIMENTAL
Intervention: DAFNE structured education programme
Number of subjects: 5000
Study: 21485666

Group type: EXPERIMENTAL
Intervention: Navigator guidance system
Number of subjects: 112

Group type: COMPARATOR
Intervention: Standard post open-heart surgery care
Number of subjects: 112
Study: 19223344

Group type: EXPERIMENTAL
Intervention: Purpose built shade sails installed in winter 2005 at full sun study sites
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control schools (no shade sails)
Number of subjects: 51
Study: 17043189

Group type: EXPERIMENTAL
Intervention: Topical calcipotriene
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simulated solar radiation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated controls
Number of subjects: 0
Study: 12622605

Group type: EXPERIMENTAL
Intervention: Self-management program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 10934569

Group type: EXPERIMENTAL
Intervention: Intensive treatment (24.52 hours per week for one year, gradually reducing over 1 to 2 years)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Parent training (3 to 9 months)
Number of subjects: 15
Study: 9013398

Group type: EXPERIMENTAL
Intervention: Velnacrine (10, 25, 50 and 75 mg t.i.d.)
Number of subjects: 735

Group type: EXPERIMENTAL
Intervention: Velnacrine
Number of subjects: 735

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 735
Study: 1424619

Group type: EXPERIMENTAL
Intervention: Mifepristone + Gemeprost
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dilapan + Gemeprost
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gemeprost alone (Control)
Number of subjects: 0
Study: 3912621

Group type: EXPERIMENTAL
Intervention: CMFVP for 1 year (ER+ patients)
Number of subjects: 0

Group type: COMPARATOR
Intervention: CMFVP for 2 years (ER- patients)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CMFVP for 1 year and/or hormonal therapy (ER+ patients)
Number of subjects: 0

Group type: COMPARATOR
Intervention: CMFVP for 1 or 2 years (ER- patients)
Number of subjects: 0
Study: 30954261

Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum DR7 (9 log cfu/d) for 12 weeks
Number of subjects: 109

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study: 29489066

Group type: EXPERIMENTAL
Intervention: OBE022 administered after a standardized breakfast on day 1 and in the fasted state from day 3 to day 9
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: OBE022 and OBE002
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Standardized meals on days 1, 3, and 9
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Food effect on the QT interval
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Change from predose, premeal and change from premeal, postdose
Number of subjects: 23
Study: 26709818

Group type: EXPERIMENTAL
Intervention: Volar locking plate
Number of subjects: 140

Group type: COMPARATOR
Intervention: External fixation with optional addition of K-wires
Number of subjects: 140
Study: 25315893

Group type: EXPERIMENTAL
Intervention: 6.0% hydrogen peroxide (White Class with Calcium, FGM)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 7.5% hydrogen peroxide (White Class with Calcium, FGM)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 7.5% hydrogen peroxide (Oral B 3D White, Oral‐B)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 24300266

Group type: EXPERIMENTAL
Intervention: Intubating Laryngeal Mask Airway (ILMA)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Direct Laryngoscope (DLS)
Number of subjects: 120
Study: 20223617

Group type: EXPERIMENTAL
Intervention: Patient engagement intervention
Number of subjects: 79

Group type: COMPARATOR
Intervention: Safety Group (contacts on a different topic)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 79
Study: 18058653

Group type: EXPERIMENTAL
Intervention: Intravenous propofol alone (group P)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Intravenous propofol with oral midazolam premedication (group M + P)
Number of subjects: 91
Study: 15734615

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 8851

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 8851
Study: 12899316

Group type: EXPERIMENTAL
Intervention: Expressive suppression
Number of subjects: 2

Group type: COMPARATOR
Intervention: Natural response
Number of subjects: 2

Group type: COMPARATOR
Intervention: Cognitive reappraisal
Number of subjects: 2
Study: 11910594

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (50 micrograms per 24 hours)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol
Number of subjects: 45
Study: 8560293

Group type: EXPERIMENTAL
Intervention: Clinic-based smoking cessation interventions, details on dosage and duration not available
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tailored counseling based on smoker's degree of addiction and readiness to quit
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Community-based anti-tobacco programs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increased taxation on cigarettes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increasing the number of smoke-free environments
Number of subjects: 0
Study: 1723378

Group type: EXPERIMENTAL
Intervention: Colfosceril palmitate (Exosurf Neonatal)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Air placebo
Number of subjects: 0
Study: 6771931

Group type: EXPERIMENTAL
Intervention: 0.4 mg nitroglycerin perlingual application
Number of subjects: 92

Group type: COMPARATOR
Intervention: 0.6 mg inhalatively given isoprenalin
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Number of subjects: 92
Study: 31135809

Group type: EXPERIMENTAL
Intervention: Breakfast in the Classroom Initiative
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 28526225

Group type: EXPERIMENTAL
Intervention: Moderate Intensity Continuous Exercise (MICE)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: High Intensity Interval Exercise (HIIE)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Moderate Intensity Interval Exercise (MIIE)
Number of subjects: 13
Study: 25922424

Group type: EXPERIMENTAL
Intervention: 12-week individual CBT plus 400 mg/day modafinil
Number of subjects: 65

Group type: COMPARATOR
Intervention: 12-week individual CBT only
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: 12-week individual CBT plus 400 mg/day modafinil (high adherent patients)
Number of subjects: 65